(Q33336492)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11263437%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

title

A phase II trial of bryostatin 1 in patients with non-Hodgkin's lymphoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11263437%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

main subject

phase II clinical trial

0 references

phase I clinical trial

0 references

author

Fiona Blackhall

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11263437%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

John Radford

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11263437%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

Gordon C. Jayson

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11263437%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

author name string

M Ranson

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11263437%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

B W Hancock

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11263437%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

M Soukop

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11263437%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

A T McGown

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11263437%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

A Robbins

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11263437%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

G Halbert

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11263437%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

Cancer Research Campaign Phase I/II Committee

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11263437%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

language of work or name

English

0 references

publication date

1 February 2001

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11263437%20AND%20SRC:MED&resulttype=core&format=json

British Journal of Cancer

5 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11263437%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

volume

84

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11263437%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11263437%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

page(s)

465-469

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11263437%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1054/bjoc.2000.1624

5 November 2019

exact match

0 references

cites work

Phase II trial of bryostatin 1 in patients with relapsed low-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363763

A Phase I trial of bryostatin-1 in children with refractory solid tumors: a Pediatric Oncology Group study.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363763

A phase II study of bryostatin 1 in metastatic malignant melanoma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363763

Potentiation of 2-chlorodeoxyadenosine activity by bryostatin 1 in the resistant chronic lymphocytic leukemia cell line (WSU-CLL): association with increased ratios of dCK/5'-NT and Bax/Bcl-2.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363763

Bryostatin 1 down-regulates mdr1 and potentiates vincristine cytotoxicity in diffuse large cell lymphoma xenografts.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363763

Bryostatin 1-tamoxifen combinations show synergistic effects on the inhibition of growth of P388 cells in vitro.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363763

Phase I study of bryostatin 1 in patients with relapsed non-Hodgkin's lymphoma and chronic lymphocytic leukemia

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363763

Modulation of bryostatin 1 muscle toxicity by nifedipine: effects on muscle metabolism and oxygen supply

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363763

In vivo administration of the anticancer agent bryostatin 1 activates platelets and neutrophils and modulates protein kinase C activity.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363763

A phase I study of intravenous bryostatin 1 in patients with advanced cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363763

Phase I study of bryostatin 1: assessment of interleukin 6 and tumor necrosis factor alpha induction in vivo. The Cancer Research Campaign Phase I Committee

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363763

The bcl-2 and p53 oncoproteins can be modulated by bryostatin 1 and dolastatins in human diffuse large cell lymphoma.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363763

A phase I trial of bryostatin 1 in patients with advanced malignancy using a 24 hour intravenous infusion.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363763

Bryostatin 1 induces apoptosis and augments inhibitory effects of vincristine in human diffuse large cell lymphoma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363763

Bryostatin 1, a novel antineoplastic agent and protein kinase C activator, induces human myalgia and muscle metabolic defects: a 31P magnetic resonance spectroscopic study

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363763

Reporting results of cancer treatment

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363763

Antineoplastic bryostatins are multipotential stimulators of human hematopoietic progenitor cells

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363763

Studies and perspectives of protein kinase C.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363763

The action of bryostatin on normal human hematopoietic progenitors is mediated by accessory cell release of growth factors

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363763

Preclinical evaluation of bryostatin as an anticancer agent against several murine tumor cell lines: in vitro versus in vivo activity

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363763

Sensitization of human cervical carcinoma cells to cis-diamminedichloroplatinum(II) by bryostatin 1

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363763

Modulation of resistance to ara-C by bryostatin in fresh blast cells from patients with AML.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363763

Differential effects of bryostatin 1 on human non-Hodgkin's B-lymphoma cell lines.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363763

Successful treatment of human Waldenström's macroglobulinemia with combination biological and chemotherapy agents

31 October 2018

1 reference

12 December 2020

Immunomodulation in patients receiving intravenous Bryostatin 1 in a phase I clinical study: comparison with effects of Bryostatin 1 on lymphocyte function in vitro

1 reference

12 December 2020

Matrix metalloproteinase inhibitors

1 reference

12 December 2020

High-performance liquid chromatographic assay for the novel antitumor drug, bryostatin-1, incorporating a serum extraction technique

1 reference

12 December 2020

Compatibility and stability of bryostatin 1 in infusion devices

1 reference

12 December 2020

The determinatio of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent

1 reference

12 December 2020

The role of protein kinase C in the regulation of cell growth and in signalling to the cell nucleus

1 reference

12 December 2020

Treatment of patients with metastatic melanoma with bryostatin-1--a phase II study

1 reference

12 December 2020

The in vivo effect of bryostatin-1 on paclitaxel-induced tumor growth, mitotic entry, and blood flow

1 reference

12 December 2020

Updated Kiel classification for lymphomas

1 reference

12 December 2020

Identifiers

DOI

10.1054/BJOC.2000.1624

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11263437%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

5 November 2019

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11263437%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

PubMed publication ID

11263437

1 reference